The 45 rating InvestorsObserver gives to Alnylam Pharmaceuticals, Inc. (ALNY) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 46 percent of stocks in the Biotechnology industry, ALNYs 45 overall rating means the stock scores better than 45 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 45 means the stock is more attractive than 45 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Alnylam Pharmaceuticals, Inc. (ALNY) stock is trading at $144.75 as of 10:40 AM on Friday, Jan 8, a rise of $5.35, or 3.84% from the previous closing price of $139.40. The stock has traded between $137.72 and $145.09 so far today. Volume today is low. So far 103,431 shares have traded compared to average volume of 509,366 shares.

Click Here to get the full Stock Score Report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the article here:
Is Alnylam Pharmaceuticals, Inc. (ALNY) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver